H.R. 5354: Gestational Diabetes Act or “GEDI” Act

H.R. 5354

Gestational Diabetes Act or “GEDI” Act

Sponsor
Rep. Eliot L. Engel

Date
September 28, 2010 (111th Congress, 2nd Session)

Staff Contact
Communications

Floor Situation

H.R. 5354 is expected to be considered on the House floor on Wednesday, September 29, 2010, under a suspension of the rules, requiring a two-thirds majority vote to pass.  Rep. Engle (D-NY) introduced H.R. 5354 on May 20, 2010, and it was referred to the Committee on Energy and Commerce.  On September 23, 2010, the committee ordered H.R. 5354 reported by voice vote.

 

Bill Summary

H.R. 5354 would require the secretary of Health and Human Services (HHS) to develop a multisite, gestational diabetes research project within diabetes program of the Centers for Disease Control and Prevention to expand and enhance surveillance data and public health research on gestational diabetes.

H.R. 5354 would require the secretary of HHS to award grants to entities for demonstration projects that implement evidence-based interventions to reduce the incidence of gestational diabetes and its recurrence and to prevent type 2 diabetes after pregnancy.

Lastly, the bill would require the director of the Centers for Disease Control to encourage postpartum follow up to reduce the incidence of gestational diabetes, its recurrence, progression to type 2 diabetes, and related complications.

H.R. 5354 would authorize $5,000,000 to be appropriated each year for fiscal years 2012 through 2016.   

Background

The prevalence of gestational diabetes in the United States is increasing and according to the findings of H.R. 5354, the medical community is in disagreement on an effective treatment.    

Cost

As of publication, the Congressional Budget Office had not released a score of H.R. 2941.